Blood Advances

Papers
(The H4-Index of Blood Advances is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer484
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19315
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease291
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma289
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma266
A neutrophil activation signature predicts critical illness and mortality in COVID-19236
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma226
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease186
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients142
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1135
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma134
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub125
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 122
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia117
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML115
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT115
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma114
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease114
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations107
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia105
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19105
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data102
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML102
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience100
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge92
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma87
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy83
Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial81
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A81
Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy78
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients77
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells77
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease76
Next-generation cell therapies: the emerging role of CAR-NK cells73
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis72
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma71
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia69
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide69
The incidence of cancer-associated thrombosis is increasing over time69
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations68
BiTEs better than CAR T cells68
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma67
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity66
Inflammasome activation in neutrophils of patients with severe COVID-1966
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis64
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy64
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort63
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia63
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy63
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study62
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma62
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection62
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial62
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial61
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis61
Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up61
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas60
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data60
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells60
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML60
0.087809085845947